Compound Evidence File
#EC-2026-0067
Retatrutide 5mg + Cagrilintide 5mg Blend
Filed under Peptides. The bureau holds 136 laboratory returns for this compound from 57 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
57 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Feb 2026 | 20 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 2 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 5 May 2026 | 21 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 25 Mar 2026 | 11 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Mar 2026 | 24 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Nov 2025 | 13 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Apr 2026 | 21 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 14 Feb 2026 | 2 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 10.0 | 10.0 | 27 May 2026 | 6 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Apr 2026 | 17 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 8 May 2026 | 11 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Apr 2026 | 13 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Jul 2026 | 18 Aug 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 10.0 | 10.0 | 10.0 | 11 Jun 2025 | 11 Jun 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Feb 2026 | 25 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Feb 2026 | 19 Aug 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 1 Mar 2026 | 5 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Jun 2026 | 3 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 25 Dec 2025 | 22 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Jun 2026 | 22 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 16 Jun 2026 | 13 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jul 2026 | 4 Aug 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 9.6 | 8.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 9.5 | 9.5 | 9.5 | 13 Jun 2025 | 13 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 9.2 | 7.7 | 10.0 | 21 May 2026 | 21 May 2026 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 9.2 | 9.2 | 9.2 | 3 Jul 2025 | 3 Jul 2025 |
| PeptiSlimCASE #VI-2026-0557 | X | 1 | 9.0 | 9.0 | 9.0 | 7 May 2025 | 7 May 2025 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 8.7 | 8.7 | 8.7 | 17 Dec 2024 | 17 Dec 2024 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 8.6 | 8.6 | 8.6 | 28 Mar 2025 | 28 Mar 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.4 | 7.2 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.3 | 7.8 | 8.9 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.2 | 7.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 7.8 | 7.8 | 7.8 | 13 Feb 2025 | 13 Feb 2025 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 7.6 | 7.6 | 7.6 | 13 Jun 2025 | 13 Jun 2025 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 7.6 | 7.6 | 7.6 | 9 Jun 2025 | 9 Jun 2025 |
| Atomik LabzCASE #VI-2026-0327 | X | 2 | 7.5 | 7.5 | 7.6 | 28 Mar 2025 | 23 May 2026 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 7.5 | 7.5 | 7.5 | 21 May 2025 | 21 May 2025 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 7.4 | 7.4 | 7.4 | 25 Apr 2025 | 25 Apr 2025 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 2 | 7.3 | 6.8 | 7.8 | 9 Jun 2025 | 24 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 4 | 6.9 | 6.1 | 8.6 | 2 Apr 2025 | 25 May 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 6.7 | 6.7 | 6.7 | 24 Apr 2025 | 24 Apr 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 6.7 | 6.7 | 6.7 | 2 Jul 2025 | 2 Jul 2025 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 2 | 6.5 | 6.0 | 6.9 | 6 May 2025 | 24 May 2026 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 6.1 | 6.1 | 6.1 | 13 Feb 2025 | 13 Feb 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 6.0 | 6.0 | 6.0 | 13 Jun 2025 | 13 Jun 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 5.9 | 5.9 | 5.9 | 20 Jun 2025 | 20 Jun 2025 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 5.5 | 5.5 | 5.5 | 28 Mar 2025 | 28 Mar 2025 |
| YimeiCASE #VI-2026-0081 | X | 1 | 5.4 | 5.4 | 5.4 | 2 Apr 2025 | 2 Apr 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 5.3 | 5.3 | 5.3 | 6 May 2025 | 6 May 2025 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 5.3 | 5.3 | 5.3 | 6 May 2025 | 6 May 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 2 | 5.0 | 4.2 | 5.8 | 2 Jul 2025 | 24 May 2026 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 4.6 | 4.6 | 4.6 | 16 Mar 2025 | 16 Mar 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 4.4 | 4.4 | 4.4 | 14 Jan 2025 | 14 Jan 2025 |
| Shanghai Wibson Biotechnology WBSCASE #VI-2026-0214 | X | 1 | 4.4 | 4.4 | 4.4 | 14 Jan 2025 | 14 Jan 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
Open any subject to view the batch-level evidence for Retatrutide 5mg + Cagrilintide 5mg Blend alone.